Invaio Sciences Acquires Peptyde Bio

Biosynth Carbosynth Acquires Pepscan

July 4, 2022

Biotechnology

Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing

September 25, 2023

Pharmaceuticals

Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.

AbbVie Completes Acquisition of Nimble Therapeutics

January 23, 2025

Biotechnology

AbbVie has completed its acquisition of Nimble Therapeutics, adding Nimble's investigational oral peptide IL23R inhibitor for psoriasis and a peptide synthesis, screening and optimization platform to AbbVie's immunology pipeline. The deal is intended to strengthen AbbVie's R&D capabilities and accelerate discovery and optimization of oral peptide therapeutics.

BioMarin Acquires Inozyme Pharma

May 16, 2025

Biotechnology

BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million ($4.00 per share). The deal adds Inozyme's late-stage enzyme replacement therapy INZ-701 for ENPP1 Deficiency to BioMarin's enzyme-therapy portfolio and is expected to accelerate development toward potential regulatory approval.